Masaaki Oka

USPTO Granted Patents = 15 (Patent Applications = 1)

CIPO Patents = 8 (Patent Applications = 8)

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 21(Granted Patents)

Location History:

Ube, JP (2010 - 2019)
Yamaguchi, JP (2020 - 2023)

Company Filing History:

F. Hoffmann-la Roche Ag

Roche Molecular Systems, Inc.

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12448413 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell (2025-10-21),

2. 11692216 - Method for assisting prediction of risk of occurrence of side effect of irinotecan (2023-07-04),

3. 11618770 - MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same (2023-04-04),

4. 11461598 - Information processing device, information processing program, and information processing method (2022-10-04),

5. 11304997 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell (2022-04-19),

6. 10875900 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-12-29),

7. 10590179 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-03-17),

8. 10537626 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell (2020-01-21),

9. 10526388 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells (2020-01-07),

10. 10450601 - Buffer composition for hybridization use, and hybridization method (2019-10-22),

11. 8927209 - Liver cancer methods and compositions (2015-01-06),

12. 8655597 - Scoring system for the prediction of cancer recurrence (2014-02-18),

13. 8140456 - Method and system of extracting factors using generalized Fisher ratios (2012-03-20),

14. 7943311 - Kits and method for determining the risk of adverse effects of irinotecan comprising hybridizing pairs of nucleic acid probes (2011-05-17),

15. 7747389 - Scoring system for the prediction of cancer recurrence (2010-06-29),

Title: Masaaki Oka: An Insight into His Career

Introduction

Masaaki Oka is a prominent professional based in Japan with an extensive career in the corporate world. Despite having no patents registered under his name, he has contributed significantly to the companies he has been a part of. His experience demonstrates the impact one can have in the fields of technology and innovation.

Latest Patents

As of now, Masaaki Oka does not hold any patents. This does not diminish his contributions, however, as his work within the industry exhibits substantial involvement in technological advancement and innovation.

Career Highlights

Masaaki Oka has built a reputable career with notable companies, including Ricoh Company, Ltd. and Cytlimic Inc. At Ricoh, a leader in imaging and electronics, he gained valuable experience that propelled his career forward. At Cytlimic, he furthered his understanding of technology and innovation in the realm of biotechnology.

Collaborations

Throughout his career, Masaaki Oka has collaborated with various professionals within the organizations he has worked for. His ability to work within teams has allowed him to contribute to numerous projects, promoting advancements within his fields of expertise.

Conclusion

While Masaaki Oka may not have any patents to his name, his professional journey through reputable companies highlights his dedication to technology and innovation. His career serves as an example for those aspiring to make a mark in their respective fields without necessarily holding patents.

This text is generated by artificial intelligence and may not be accurate.